Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||
| DOI | 10.3201/EID2710.210735 | ||
| Año | 2021 | ||
| Tipo |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Andes virus, an orthohantavirus endemic to South America, causes severe hantavirus cardiopulmonary syndrome associated with human-to-human transmission. No approved treatments or vaccines against this virus are available. We show that a combined treatment with 2 monoclonal antibodies protected Syrian hamsters when administered at midstage or late-stage disease.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Williamson, Brandi N. | Mujer |
NIAID Rocky Mountain Laboratories - Estados Unidos
|
| 2 | Prescott, Joseph | Hombre |
NIAID Rocky Mountain Laboratories - Estados Unidos
Robert Koch Institut - Alemania Robert Koch Institute - Alemania |
| 3 | Luis Garrido, Jose | Hombre |
Ichor Biologics LLC - Estados Unidos
Universidad de Concepción - Chile |
| 4 | Alvarez, Raymond | Hombre |
Ichor Biologics LLC - Estados Unidos
|
| 5 | Feldmann, Heinz | Hombre |
NIAID Rocky Mountain Laboratories - Estados Unidos
|
| 6 | BARRIA-CARCAMO, MARIA INES | Mujer |
Universidad de Concepción - Chile
Universidad San Sebastián - Chile |
| Fuente |
|---|
| National Institutes of Health |
| National Institute of Allergy and Infectious Diseases |
| Small Business Innovation Research |
| National Agency for Research |
| Agradecimiento |
|---|
| This work was partially funded by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health. M.I.B. was partially supported by the National Agency for Research and Development/FONDEF (ID14I20084) in collaboration with Ichor Biologics. J.L.G. and R.A. were partially supported by a Small Business Innovation Research grant through the NIAID (grant R43 AI138740-01A1). |